From Nasdaq: 2025-05-26 00:43:00

Moderna (NASDAQ: MRNA) has seen a strong rebound in its stock price after the FDA recommended annual COVID-19 shots for high-risk populations. However, its stock is still far below its 52-week high, reflecting concerns about falling vaccine revenues and lack of growth drivers. Peers like Pfizer and Sarepta Therapeutics did not see similar gains, indicating the rally may be short-lived.

Despite the recent price gains, Moderna’s fundamentals remain weak. Revenues have dropped significantly year-over-year, with the company reporting a net loss of $3.4 billion over the last four quarters. The stock has also shown high sensitivity to market downturns, underperforming during crises like COVID-19 and the 2008 financial crisis.

Compared to its peers, Moderna faces deeper financial challenges and a less diverse product portfolio. While its valuation may seem reasonable on the surface, risks like declining revenue visibility and high cash burn suggest underlying vulnerabilities. The recent stock rally may have been driven by regulatory news rather than sector-wide momentum.

Investors should approach Moderna’s recent rally with caution, as the company continues to struggle with declining revenues and mounting losses. While the FDA’s guidance provided a boost, sustained growth will require tangible improvements in revenue trends and pipeline progress. The stock’s current valuation may not fully account for the risks ahead, making it important to monitor the company’s performance closely.



Read more at Nasdaq: Can Moderna Stock Keep Its Rally Going?